drugset
drugset / Trial / NCT01187303

Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)

NCT01187303 ↗

Phase 2 Completed 28 enrolled University of Cologne
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this trial is to determine the efficacy of ofatumumab in patients with relapsed nodular lymphocyte predominant Hodgkin lymphoma (NLPHL).

Timeline

Start
2011-05
Primary completion
2013-11
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Ofatumumab Monoclonal antibody 1000 mg/m2 —

Indications

nodular lymphocyte predominant Hodgkin lymphoma